Needham & Co Downgrades Anesiva (ANSV) to Hold
More News related to ANSV
- Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
- Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger
- Anesiva Receives Nasdaq Listing Compliance Notice
- Needham & Co Downgrades Anesiva (ANSV) to Hold
- Anesiva (ANSV) Announces FDA Approval of sNDA to Expand Zingo(TM) Indication to Include Adults
Needham & Co downgrades Anesiva (Nasdaq: ANSV) from Buy to Hold.
Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
